Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Multicenter, Phase Ib/II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection in Patients With Advanced Gastric/ Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer

Next Previous
X
Search
Trial Profile

An Open, Multicenter, Phase Ib/II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection in Patients With Advanced Gastric/ Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Satricabtagene autoleucel (Primary) ; Docetaxel; Irinotecan; Nivolumab; Paclitaxel; Rivoceranib
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CARsgen

    • Most Recent Events

    • 30 Dec 2024 According to a CARsgen media release, company anticipate submitting an NDA to the NMPA in the first half of 2025.
    • 30 Dec 2024 Primary endpoint (Phase II: Progression-free survival (PFS), as assessed by IRC, of CT041 autologous CAR T-cell injection versus Physicians Choice) has been met.
    • 30 Dec 2024 Results published in the CARsgen Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top